E

    Evotec SE ADR (EVO)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $1.88
    -0.03 (-1.57%)

    Market Cap: $678.79M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    28%(5/18)
    Avg Surprise
    -170.37%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.30
    Range$-0.36 - $-0.25
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate Drift
    90d ago$-0.07+77.0%
    60d ago$-0.07+77.0%
    30d ago$-0.20+32.8%
    7d ago$-0.20+32.8%
    Current$-0.30
    Revenue Consensus
    $136M
    Range$127M - $144M
    2 analysts
    Dec 31, 2026
    EPS Consensus$-1.02
    Range$-1.12 - $-0.92
    2 analysts
    Revenue Consensus
    $158M
    Range$136M - $239M
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.02---
    Sep 26EST
    		-$-0.30---
    Jun 26
    		$-0.13$-0.04-225.00%Miss-8.3%
    Mar 26
    		$-0.34$-0.17-100.00%Miss-277.8%
    Dec 25
    		$0.04$0.07-35.71%Miss+139.1%
    Sep 25
    		$-0.12$-0.17+29.41%Beat-9.1%
    Jun 25
    		$-0.12$-0.13+7.69%Beat-33.3%
    Mar 25
    		$-0.09$-0.12+25.00%Beat-200.0%
    Dec 24
    		$-0.12$0.00N/AMiss-130.0%
    Sep 24
    		$-0.11$-0.12+8.33%Beat+8.3%
    Jun 24
    		$-0.09$-0.01-800.00%Miss-125.0%
    Mar 24
    		$-0.03$-0.03+0.00%Beat+57.1%
    Dec 23
    		$-0.05$-0.03-66.67%Miss+61.5%
    Sep 23
    		$-0.12$-0.05-140.00%Miss+7.7%
    Jun 23
    		$-0.04N/A-136.36%Miss+50.0%
    Mar 23
    		$-0.07N/A-133.33%Miss+65.0%
    Dec 22
    		$-0.13$0.10-230.00%Miss-18.2%
    Sep 22
    		$-0.13$0.15-186.67%Miss-106.9%
    Jun 22
    		$-0.08$0.03-366.67%Miss-109.1%
    Mar 22
    		$-0.20$0.06-433.33%Miss-125.8%
    Dec 21
    		$-0.11$0.06-283.33%Miss-2920.5%
    Sep 21
    		$1.88N/AN/ABeat+8723.9%
    Jun 21
    		$0.88N/AN/ABeat+714.9%
    Mar 21
    		$0.77N/AN/ABeat+210.5%
    Dec 20
    		$0.00N/AN/ABeat-96.6%
    Sep 20
    		$-0.02N/AN/ABeat-130.8%
    Jun 20
    		$-0.14N/AN/ABeat-1491.1%
    Mar 20
    		$0.25N/AN/ABeat+401.4%
    Dec 19
    		$0.12N/AN/ABeat-3.7%
    Sep 19
    		$0.07N/AN/ABeat-87.0%
    Jun 19
    		$-0.01N/AN/ABeat-103.9%
    Mar 19
    		$0.05N/AN/ABeat-13.9%
    Dec 18
    		$0.12N/AN/ABeat-26.8%
    Sep 18
    		$0.55N/AN/ABeat+1040.4%
    Jun 18
    		$0.23N/AN/ABeat+359.2%
    Mar 18
    		$0.06N/AN/ABeat-46.7%
    Dec 17
    		$0.16N/AN/ABeat+177.9%
    Sep 17
    		$0.05N/AN/ABeat+28.5%
    Jun 17
    		$0.05N/AN/ABeat-
    Mar 17
    		$0.11N/AN/ABeat-
    Dec 16
    		$0.06N/AN/ABeat-
    Sep 16
    		$0.04N/AN/ABeat-

    Dividends

    Dividend Metrics

    Yield0.00%
    Annual/Share$0.00
    Frequency12
    No dividend payments in the selected period.
    View EVO's full dividend history

    Key Metrics

    Valuation
    P/E Ratio-3.45EV/EBITDA34.36x
    Price/FCF-3.48xFCF Yield-28.70%
    Profitability
    Profit Margin-27.50%Operating Margin-62.30%
    ROE-26.10%ROIC-33.89%
    Financial Health
    Debt/Equity0.09xInterest Coverage-20.91x
    Current Ratio2.33xQuick Ratio2.21x
    Trading Statistics
    Beta1.26Avg Volume61.79K
    52-Week High$4.2752-Week Low$1.87

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.93
    SMA 20$1.97
    SMA 50$2.21
    SMA 200$2.86
    EMA 10$1.93
    EMA 20$1.97
    EMA 50$2.17
    EMA 200$2.80

    MACD

    Line: -0.07Signal: -0.08Hist: 0.01

    ADX

    ADX: 23.0+DI: 20.9-DI: 33.8

    Aroon & PSAR

    Aroon Up48.0
    Aroon Down100.0
    PSAR$2.04

    Bollinger Bands

    Upper Band$2.13
    Lower Band$1.82
    %B Position1557%(Upper)
    Band Width0.20

    RSI (14-Day)

    Neutral
    38.5

    Momentum Oscillators

    Stoch %K16.1
    Stoch %D19.5
    Williams %R-94.1
    ROC (10d)-4.1%
    Momentum-0.08
    CCI (20d)-117.3
    MFI (14d)28.6

    Volatility Measures

    ATR (14d)$0.07(3.7%)
    StdDev (20d)0.08
    Hist Vol46.9%(High)

    Volume Flow

    VWAP$1.88
    OBV665.0K
    AD Line-1.2M
    CMF (20d)0.289

    Volume Metrics

    Avg Vol (20d)60.9K
    Vol Ratio1.1x
    VWMA (20d)$1.98

    Pivot Points

    R3$1.98
    R2$1.97
    R1$1.94
    Pivot Point$1.92
    S1$1.89
    S2$1.88
    S3$1.85

    Advanced Oscillators

    TSI-20.55
    Ultimate Osc46.1
    KST-93.27

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$145.85M$159.22M$253.27M$163.89M$171.24M$199.98M$221.23M$184.89M$182.12M$208.73M$201.31M$196.28M
    Cost of Revenue$147.46M$160.81M$174.81M$163.95M$162.64M$172.75M$175.13M$166.61M$166.38M$173.97M$163.65M$158.45M
    Gross Profit$-1,606,159$-1,593,785$78.46M$-62,000$8.59M$27.23M$46.10M$18.28M$15.74M$34.76M$37.67M$37.82M
    Operating Expenses$50.37M$54.75M$216.06M$44.44M$36.37M$47.23M$213.10M$44.78M$120.35M$52.97M$49.21M$50.01M
    R&D$10.43M$10.25M$9.83M$8.71M$8.21M$10.76M$9.73M$11.87M$13.01M$16.24M$9.15M$17.50M
    SG&A$0$43.79M$44.35M$42.31M$41.61M$47.70M$49.90M$46.39M$45.97M$45.94M$42.13M$39.29M
    Operating Income$-51,973,512$-56,348,643$37.21M$-44,502,000$-27,773,000$-20,008,000$8.13M$-26,493,000$-104,606,000$-18,207,000$-11,547,000$-12,187,000
    Interest Income$0$1.79M$1.16M$841,000$1.21M$1.22M$367,000$917,000$467,000$1.42M$1.10M$2.48M
    Interest Expense$3.02M$2.63M$3.76M$2.28M$6.00M$2.41M$4.42M$1.87M$2.74M$2.67M$3.18M$3.52M
    Income Before Tax$-48,916,724$-124,189,208$29.46M$-42,960,000$-43,419,000$-29,851,000$-15,866,000$-46,874,000$-85,409,001$-14,564,001$-24,025,000$-29,916,000
    Income Tax Expense$-1,495,354$-248,012$0$127,000$59,000$1.73M$0$-7,241,000$9.52M$6.11M$-7,895,000$9.04M
    Net Income$-47,421,370$-123,941,196$14.62M$-43,087,000$-43,478,000$-31,577,000$-40,839,000$-39,634,000$-94,932,000$-20,673,000$-16,131,000$-38,955,000
    EBITDA$-27,129,875$-97,352,021N/A$-17,643,000$-3,422,000$-27,444,000N/A$-19,698,000$-11,746,500$-437,500$2.98M$12.22M
    EBIT$-51,973,512$-121,563,732N/A$-42,960,000$-28,599,000$-11,449,000N/A$-45,008,000$-36,151,000$-18,208,000$-20,844,000$-12,175,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EVO

    News

    Evotec stock holds just above its 52-week low as profit warning and Q2 2026 loss reset guidance

    Evotec SE's stock is trading just above its 52-week low after the company issued a profit warning and reported a significant adjusted EBITDA loss in Q2 2026. This led to a sharp cut in full-year guidance for 2026, with anticipated revenue between EUR570 million and EUR610 million and an adjusted EBITDA loss ranging from EUR70 million to EUR105 million. The company is undergoing a significant restructuring program, shifting the investment narrative from growth to recovery and balance-sheet resilience.

    Ad-hoc-news.de•8/26/26•
    Neutral

    Evotec stock struggles after profit warning as Q2 2026 figures and guidance cuts weigh on sentiment

    Evotec's stock is struggling in late August 2026 after a profit warning and weak Q2 2026 results led to significantly reduced full-year guidance. The company now projects lower revenue and an adjusted EBITDA loss for 2026, driven by declining segment revenues, restructuring costs from its Horizon program, and an impairment charge. Despite these near-term challenges, Evotec is pushing forward with its transformation strategy, funded in part by a recent convertible bond issuance, aiming to re-focus its drug discovery and biologics platforms for long-term growth.

    Ad-hoc-news.de•8/25/26•
    Bearish

    Evotec stock softens as Project Horizon funding highlights Q2 2026 pressure

    Evotec SE's stock is under pressure after reporting weaker Q2 2026 earnings compared to the prior year, leading to a decline in revenue and net income. The company secured €116.1 million through a convertible bond to fund its "Project Horizon" transformation program, aimed at strengthening its balance sheet and investing in long-term initiatives. Trading in late August 2026 saw Evotec shares in the low single-digit euro range, reflecting a reset in investor sentiment due to earnings headwinds and capital structure changes.

    Ad-hoc-news.de•8/24/26•
    Neutral

    Evotec stock steadies after convertible bond funds Project Horizon

    Evotec SE's stock is trading in the low single-digit euro range in late August 2026, as the company secured €116.1 million through a convertible bond to fund its "Project Horizon" transformation program. This financing comes amidst Q2 2026 results showing revenue and net income under pressure compared to the previous year. The convertible bond aims to strengthen the balance sheet and provide flexible financing for strategic initiatives without issuing equity at depressed valuations, while investors weigh the risks and opportunities of the transformation.

    Ad-hoc-news.de•8/24/26•
    Somewhat-Bearish

    Evotec stock slides near 52-week low after first-half loss

    Evotec's stock is trading near its 52-week low after the company reported a first-half 2026 revenue of EUR300.1 million and an adjusted EBITDA of negative EUR42.7 million. Management maintained its full-year guidance, which suggests further deepening of losses in the second half. Analysts are cautious, with the stock price significantly below the average target price.

    Ad-hoc-news.de•8/21/26•
    Neutral

    Frequently Asked Questions About EVO

    Does EVO pay dividends?
    Evotec SE ADR (EVO) has a dividend payment track record. See the EVO dividend history page for its current payment status, yield, and streaks.
    What is EVO's market cap?
    Evotec SE ADR (EVO) has a market capitalization of $678.79M with a current stock price of $1.88.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In